

A Systematic Overview of Radiation Therapy Effects in Hodgkin's Lymphoma

Anita Gustavsson, Birgitta Osterman and Eva Cavallin-Ståhl

From the Department of Oncology, University Hospital, Lund (A. Gustavsson, E. Cavallin-Ståhl) and the Department of Oncology, University Hospital, Umeå (B. Osterman), Sweden

Correspondence to: Anita Gustavsson, Department of Oncology, University Hospital, SE-221 85 Lund. Tel: +46 46 17 7520/8183. Fax: +46 46 17 6080. E-mail: anita.gustavsson@onk.lu.se

Acta Oncologica Vol. 42, No. 5/6, pp. 589–604, 2003

A systematic review of radiation therapy trials in several tumour types was carried out by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357–365). This synthesis of the literature on radiation therapy for Hodgkin's lymphoma (HL) is based on data from 12 randomized trials and 2 meta-analyses. Data from 3 prospective studies, 29 retrospective studies and 58 other articles were also used. In total, 58 scientific articles are included, involving 27 280 patients. The results were compared with those of a similar overview from 1996 including 38 362 patients. The conclusions reached can be summarized thus:

- Solid scientific documentation shows that in patients with HL more than 80% in the early stages and 60–70% of younger patients in advanced stages of disease are now cured by the development of radiotherapy and combination chemotherapy.
- Long-term follow-up shows that after 15 to 20 years the mortality from HL in early and intermediate stages is exceeded by other causes of death, mostly secondary malignancies and cardiac deaths, especially myocardial infarction.
- Convincing data show that radiotherapy plays a major role in the development of solid cancers and cardiovascular disease, but no randomized trials have been performed.
- During the past decade increasing awareness of fatal long-term sequelae has fundamentally changed treatment strategies in early and intermediate stages. A thorough long-term follow-up is essential to evaluate the effects of the modifications of the therapy.
- In early stages of disease extended field irradiation is now replaced by short periods of chemotherapy followed by limited radiotherapy to decrease late sequelae. This approach is strongly supported by early reports from randomized trials. Final results cannot be fully evaluated for many years.
- The optimal radiation dose and volume after chemotherapy are not defined or if irradiation is needed at all. Several studies are under way.
- In intermediate stages two recently reported randomized trials indicate that combined modality therapy is preferable and that involved field could replace extended field irradiation. It is still too early to draw any firm conclusions.
- In advanced stages, there is no evidence of any survival benefit from additional radiotherapy.
- The role of radiotherapy in the case of residual tumour and bulky disease still remains controversial.
- There is no scientific support for improved survival with radiotherapy in conjunction with high-dose chemotherapy with stem-cell support.
- Radiotherapy as salvage treatment might be an alternative in late limited nodal recurrence after initial chemotherapy. However, the body of knowledge is small.
- The role of radiotherapy in the treatment of HL is decreasing.

Received 7 May 2003

Accepted 3 June 2003

In the year 2000, 176 cases of Hodgkin's lymphoma (HL) were diagnosed in Sweden corresponding to less than 0.5% of all new malignant tumour diagnoses (1). The age distribution is unusual since there are two age peaks, the first in patients in their 20s, and the second in their 70s. Until the 1960s, HL was considered to be incurable, but advances in radiotherapy and chemotherapy have made

cure possible in a large number of cases, particularly among young patients.

Population-based studies in Sweden show an overall survival above 90% in early and intermediate stages and about 75% in advanced stages for patients younger than 60 years (2–4). For patients above the age of 60 years the overall survival is nearly 50% (5). Very few other popula-

tion-based studies have been reported. A register study from the EUROCARE database comprising over 7 000 patients with HL diagnosed in Europe in 1985–1989 reported 72% (range 45 to 76%) age-standardized 5-year relative survival rates and a progressive decline in relative survival with increasing age (6). For the same period of time the National Cancer Data Base in the USA reported 83% 5-year overall survival in more than 14 000 patients with HL, also with a decreasing survival with increased age (7). But in this study only 18% of the patients were above 60 years of age compared with 33% in Sweden (1).

Radiotherapy and chemotherapy, alone or in combination, are curative treatment methods. A systematic review of chemotherapy trials in HL by the SBU was recently reported (8). The choice of therapy depends on the stage of the disease, the presence or absence of various prognostic factors and attempts to avoid long-term effects of treatment. Generally, a division into early and advanced stage disease is recognized (Cotswold stage I–II vs. III–IV) (Table 1). Many study groups subdivide patients with early stages into favourable and unfavourable (or intermediate stage) subgroups. The criteria for adverse prognostic factors are not entirely uniform between different study groups especially concerning early stages (Table 2). For the advanced stages, the International Prognostic Factor Project analysed data on more than 5 000 patients from 25 centres and found a prognostic score (IPS) which has been widely recognized (9). The IPS includes 7 adverse factors: ≥ 45 years, male sex, anaemia, decreased serum albumin, stage IV, leukocytosis and lymphopenia. Recently, the predictive power of IPS for advanced HL was assessed in unfavourable early stage patients but showed only modest predictive ability (10).

SUMMARY OF THE EARLIER REPORT, SBU 129/2

The synthesis of the literature on radiotherapy for HL was based on 104 scientific articles, including 2 meta-analyses, 22 randomized studies, 5 prospective studies and 58 retrospective studies.

Conclusions

The literature review clearly showed that radiotherapy was a cornerstone in the treatment of localized HL. At early stages, long-term survival was 80% to 90% when treatment was tailored to known prognostic factors.

There was a tendency towards increased use of chemotherapy as additional treatment, but no evidence that it increased survival.

To further improve survival following radiotherapy, attempts were made to reduce long-term toxicity by better defining of the patient groups who required lower radiation volumes, and delivering a dose that was as low as possible to avoid secondary solid tumours or delayed cardiopulmonary or gastrointestinal side effects, while not jeopardizing therapeutic results.

In advanced disease, radiotherapy may be needed as a complement to chemotherapy in order effectively to control bulky disease.

For recurrent disease, radiotherapy may be considered as relapse treatment or additional therapy in conjunction with high-dose chemotherapy.

Discussion

In the previous report (SBU-report 129/2, 1996) it was stated that radiotherapy was a cornerstone of treatment for localized HL with a long-term survival of 80–90% when treatment was tailored to known prognostic factors.

Since then increasingly more reports about the long-term effects have questioned that statement.

Although most young patients are cured of HL, they do not have the same life expectancy as the ordinary population. Several investigations have shown that with long-term follow up the cumulative HL-specific mortality levels off over time but the treatment-related mortality, especially second malignancies and cardiac diseases, continue to rise and now begin to exceed the mortality due to HL (11).

Clinical trials nowadays are tailored after known prognostic factors. Current clinical studies are being conducted to evaluate the use of chemotherapy together with smaller radiation fields and/or lower radiation doses, chemotherapy

Table 1

The Cotswold Staging Classification

Stage I	Involvement of single lymph node region or lymphoid structure (e.g. spleen, thymus, Waldeyer's ring)
Stage II	Involvement of two or more lymph node regions on the same side of the diaphragm (the mediastinum is a single site, hilar lymph nodes are lateralized). The number of anatomical sites should be indicated by a suffix (e.g. II ₃)
Stage III	Involvement of lymph node regions or structures on both sides of the diaphragm
III ₁	With or without splenic hilar, coeliac, or portal nodes
III ₂	With para-aortic, iliac, mesenteric nodes
Stage IV	Involvement of extranodal site(s) beyond that designated 'E'
A	No symptoms
B	Fever, drenching sweats, weight loss
X	Bulky disease ($> 1/3$ widening of mediastinum, > 10 cm maximum dimension of nodal mass)
E	Involvement of extra lymphatic tissue, contiguous or proximal to known nodal site. A single extralymphatic site as the only site of disease is classified IE

Table 2
Adverse prognostic factors in early stages recognized by three different study groups

GHSB	EORTC	NCI Canada
Large mediastinal mass (mediastinal-thoracic ratio ≥ 0.33)	Large mediastinal mass (mediastinal-thoracic ratio ≥ 0.35)	Histology: MC or LD
Elevated erythrocyte sedimentation rate (≥ 50 mm without or ≥ 30 mm with B-symptoms)	Elevated erythrocyte sedimentation rate (≥ 50 mm without or ≥ 30 mm with B-symptoms)	Elevated erythrocyte sedimentation rate
≥ 3 lymph node regions involved	≥ 4 lymph node regions involved	≥ 4 lymph node regions involved
Extranodal involvement	Age ≥ 50 years	Age > 40 years

Abbreviations: GHSB = German Hodgkin Study Group; EORTC = European Organization for the Research and Treatment of Cancer; NCI = National Cancer Institute.

without radiation therapy, fewer courses of chemotherapy and alternative chemotherapy combinations, but many of these studies are ongoing or the results are not yet published in full articles or the follow-up time is too short to be properly evaluated. Furthermore, freedom from relapse is no longer the most important endpoint of clinical trials. Efforts and studies strive to reduce morbidities of all kinds without compromising the excellent survival results.

Literature

The articles on which the conclusions in the SBU 129/2 report were based were classified and graded as follows (Number of studies/number of patients)

	1 = High	2 = Moderate	3 = Low	Total
M	–	2/5 068	–	2/5 068
C	8/5 749	11/2 341	3/291	22/8 381
P	–	5/930	–	5/930
R	14/20 587	25/2 646	19/750	58/23 983
L	6	1	–	7
O	6	4	–	10
Total	34/26 336	48/10 985	22/1 041	104/38 362

Abbreviations: M=meta analysis; C=controlled clinical trial; P=prospective trial; R=retrospective study; L=literature review; and O=other studies.

ASSESSMENT OF NEW LITERATURE

Search method and selection

The assessment of the literature covers the time period from 1994 to October 2001; studies on children are not included. A literature search was performed in Medline with use of the MeSH terms 'Hodgkin disease' in combination with 'radiotherapy' as the subheading, with limitation to meta-analyses, randomized controlled studies and controlled studies. In addition, prospective studies and in some cases retrospective studies with essential information identified through search in Medline or by scrutinizing reference lists

have also been reviewed. Furthermore, conference proceedings of recently closed but not published randomized trials are included in the reference list for information and in Overviews 2, 3 and 4. Search was also performed in the Cochrane Library.

One randomized trial was excluded: Aviles & Delgado 1998 (12): too low a quality in radiotherapy, presentation and probably in follow-up.

OVERVIEW OF NEW STUDIES

Early stages (stage I–II without adverse prognostic factors) and Intermediate stages (stage I–II with adverse prognostic factors)

Radiotherapy alone; evaluating radiation field size or dose. See Overview 1, for a description of the trials, trial results and conclusions (13–16).

Radiotherapy versus chemotherapy. Two randomized studies have earlier compared radiotherapy with MOPP chemotherapy and come to different conclusions (see previous report, SBU-report 129/2, 1996). However, these studies are not relevant today because of the use of staging laparotomy and suboptimal chemotherapy. The NCI in Canada is performing a randomized trial in patients below 40 years of age with favourable prognosis comparing subtotal nodal irradiation (STNI) including splenic irradiation with 4–6 cycles of ABVD alone (see Overview 2). No published results are available yet (see Addendum after the text).

Radiotherapy alone versus chemotherapy plus radiotherapy. See Overview 2, for a description of the trials, trial results and conclusions (13, 17–24).

One meta-analysis, including older studies (1967–1988) (13) and two recent, randomized trials (18, 20) are reported and the results are consistent. Two trials have not yet been finally reported and it will take many years to derive the mature results of these studies (17, 19). One prospective randomized trial is ongoing in the UK and is still open for accrual (see Addendum).

Chemotherapy plus radiotherapy versus chemotherapy alone. In the SBU-report 129/2, 1996, one study reported

Overview 1

Hodgkin's lymphoma. Radiotherapy alone: evaluating radiation field size or dose

Author Year (Ref. no.) Design	Aim/Study question	Patient population	Results	Conclusion/Comments
Specht 1998 (13) M	Reduced RT volume. A: more extensive RT B: less extensive RT	1962–1982, 8 trials St IA–IIIB mostly IA, IIA A: 1005 pts B: 969 pts	OS% A 77 B 77 ns TF%, at 10 y 31 43 p < 0.00001	More extensive RT reduces recurrences but no difference in OS. Increased mortality from recurrent HL in pts receiving smaller field irradiation balanced by increased treatment related mortality with more extensive RT. M1/3888
Brinker 1994 (14) O	Optimal dose for disease control	4117 radiation fields from the 1960s to the 1990s	No dose-response above 32.5 Gy	32.5 Gy could be the optimal dose. Re-analysis of retrospective data. In previous SBU-report 129/2, Ref no. 94. O2
Dühmke 1996 (15) C	Reduced radiation dose A: EF 40 Gy B: EF 30 Gy + IF 10 Gy	1988–1993 St IA–IIIB A: 170 pts B: 175 pts	OS% A 93 B 98 ns PV no PV FFTF%, at 5 y 70 81 p < 0.03 70 82 p < 0.04	30 Gy is sufficient for subclinical involvement. Definition of EF is missing. PV in 1/3 of the patients. PV had prognostic significance in this study. C2/345
Mendenhall 1999 (16) R	Optimal dose for disease control TNI/STNI mostly 30–40 Gy	1967–1994 169 pts St I–II	No increased tumour control for doses above 30 Gy	30 Gy seems to be a sufficient dose. Increased rate of local failure with increasing tumour size. R2/169

Abbreviations: EF = extended field; IF = involved field; FFTF = freedom from treatment failure; HL = Hodgkin's lymphoma; ns = not significant; OS = overall survival; pts = patient(s); PV = protocol violations; RT = radiotherapy; STNI = subtotal nodal irradiation; TF = treatment failure; TNI = total nodal irradiation; y = year(s).

better relapse-free survival with combined modality treatment, but no difference in overall survival. No new trial has been reported but four new studies are underway (MSKCC in New York, NCI Canada/ECOG, GHSG HD13 and CALGB) (see Addendum).

Radiation volume or dose after chemotherapy. See Overview 3, for a description of the trials, trial results and conclusions (21, 27).

A few randomized trials have evaluated whether the addition of chemotherapy to radiotherapy would admit a reduction of radiation volume or dose. Some recent trials concerning the same question have only been reported in abstracts. There are also two ongoing German trials (GHSG HD10 and HD11) testing 20 vs. 30 Gy to involved fields in early and intermediate stages after 2 or 4 courses of chemotherapy.

The question of whether radiotherapy is needed at all is not addressed in these trials. But there is an ongoing EORTC H9-F trial, which compares three dose levels, 36, 20 and 0 Gy to involved fields in patients in complete remission after 6 cycles of chemotherapy (See Addendum).

The literature shows that:

- More extensive radiotherapy fields substantially reduce recurrence rate but overall survival is not significantly affected.
- The addition of chemotherapy to radiotherapy reduces recurrence rate but overall survival is not significantly affected.

- The optimal dose is not definitely defined. For sub-clinical disease 30 Gy is sufficient and 30–32 Gy might be the optimal dose for tumour control. After chemotherapy, the radiation dose can be reduced to 20 Gy to non-bulky sites.
- In the early stages, extended radiotherapy could be replaced by reduced irradiation after or integrated with chemotherapy.
- The current approach with brief chemotherapy followed by limited radiotherapy is now supported by five randomized trials. However, they are only published as abstracts as yet.
- The question of whether radiotherapy is needed at all in the early stages (and intermediate stages) has not yet been answered in controlled studies.

Early and intermediate stages

	1 = High	2 = Moderate	3 = Low	Total
M	1/3 888	–	–	1/3 888
C	1/258	2/671	3/405	6/1 334
R	–	1/169	–	1/169
O	–	1	–	1
Total	2/4 146	4/840	3/405	9/5 391

Abbreviations: See above. The classification of each publication is given in the reference list.

Overview 2

Hodgkin's lymphoma. Radiotherapy alone versus chemotherapy + radiotherapy

Author Year (Ref. no.) Design	Aim/study question	Patient population	Results			Conclusion/Comments
Specht 1998 (13) M	Benefit of adding CHT to RT A: RT+CHT B: RT only	1967–1988, 13 trials St IA–IIIB A: 839 pts B: 856 pts	OS% A 79 B 77 ns	TF%, at 5 y 16 33 p < 0.00001		Addition of CHT reduces recurrences but does not significantly affect OS. Mostly MOPP or variants were used. In some studies more extensive RT was given to pts not receiving CHT; in some studies pts with advanced stages were included. However, subgroup analyses showed similar reduction of TF. M1/3888
Sieber 2001 (17) C	Benefit of neo- adjuvant CHT A: RT B: ABVD × 2+RT	1994–1998 St IA–II no risk factors A: 282 pts B: 289 pts	OS% A 98 B 98	FFTF%, at 22 m 84 96 p < 0.05		Neoadjuvant CHT reduces the relapse frequency but no difference in survival. Abstract, short follow up.
Press 2001 (18) C	Benefit of neo- adjuvant CHT A: STNI B: CHT+STNI	1989–2000 St I–IIA no bulk A: 161 B: 165	OS% A 96 B 98 ns	FFS%, at 3 y 81 94 p < 0.001		Neoadjuvant CHT reduces the relapse frequency but no difference in OS. C2/326
Radford 2001 (19) C	Benefit of neo- adjuvant CHT A: RT B: VAPEC-B × 1+RT	1989–1997 St I–IIA no bulk A: 63 pts B: 62 pts	FFP%, at 5 y A 62 B 93 p = 0.0002			Brief (4 weeks) neo-adjuvant CHT gives a significant improvement of FFP. No difference in survival. Abstract
Enrici 1999 (20) C	Benefit of neo- adjuvant CHT A: STNI B: ABVD × 1+STNI	1983–1989 St I–IIA no bulk A: 37 pts B: 36 pts	OS% A 97 B 92 ns	RFS%, at 10 y 73 94 p < 0.01		Neoadjuvant CHT reduces the relapse frequency but no difference in OS. Few patients, low power. C3/73
Noordijk 1994 (21) 1997 (22) C	Reduced RT volume A: STNI B: EBVP × 6+RT IF	1988–1993 St I–II 'favourable' A: 165 pts B: 168 pts	OS% A 96 B 98 ns	RFS%, at 6 y 81 92 p = 0.004		With CHT possible to reduce RT volume. RFS better with CHT, but no difference in OS. In the report (1994) short follow-up. C3/254 In the abstract (1997) more patients and longer follow-up. C3/–
Meerwaldt 2001 (23) C	Reduced RT volume A: STNI B: MOPP/ABV × 3 +RT IF	1993–1999 St I–II 'favourable' A: 272 pts B: 271 pts	OS% A 96 B 99 ns	TFFS%, at 46 m 77 99 p < 0.001		With CHT possible to reduce RT volume. RFS better with CHT, but no difference in OS. C3–
Horning 1997 (24) C	Reduced RT volume and dose A: STNI B: VBM × 2+RT IF+VBM × 4	1988–1995 St I–II A: 43 pts B: 35 pts	OS% A No B diff.	FFP%, at 5 y 92 87		No difference in outcome. With CHT possible to reduce RT volume and dose. Alteration of the inclusion criteria during the study but probably without significance. Few patients, low power. C3/78

Abbreviations: CHT = chemotherapy; EF = extended field; IF = involved field; FFP = freedom from progression; FFS = failure free survival; FFTF = freedom from treatment failure; m = month(s); OS = overall survival; pts = patient(s); PV = protocol violations; RFS = relapse free survival; RT = radiotherapy; STNI = subtotal nodal irradiation; TF = treatment failure; TFFS = treatment failure free survival; y = year(s); ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; EBVP = epirubicin, bleomycin, vinblastine, prednisone; MOPP = mustine, vincristine, procarbazine, prednisone; VAPEC-B = vincristine, doxorubicin, prednisolone, etoposide, cyclophosphamide, bleomycin; VBM = vinblastine, bleomycin, methotrexate.

Advanced stages: stages III and IV

The therapy of choice in advanced disease is combination chemotherapy and 60–90% of patients achieve complete remission. Approximately one-third of these patients suffer relapse, with 80% of the recurrences within 3 years and 40–50% of the patients become long-term survivors (reviewed and evaluated in SBU-report 155/2, 2001) (8). Recently, data from 25 centres on about 5 000 patients with advanced

Hodgkin's disease treated in the 1980s with combination chemotherapy with or without radiotherapy have been collected and evaluated. This International Prognostic Factors Project on advanced Hodgkin's disease has developed a 7-factor prognostic scoring system where each adverse factor reduced freedom from progression rate by 8%. After 5 years the freedom from progression was 84% with no adverse prognostic factor present and 42% with five

Overview 3

Hodgkin's lymphoma. Radiation volume or dose after chemotherapy

Author Year (Ref. no.) Design	Aim/study question	Patient population	Results	Conclusion/comments
Noordijk 1994 (21) 1997 (22) C	Reduced RT volume A: STNI B: EBVP × 6 + RT IF	1988–1993 St I–II 'favourable' A: 165 pts B: 168 pts	OS% A 96 B 98 ns RFS%, at 6 y 81 92 p = 0.004	With CHT possible to reduce RT volume. RFS better with CHT, but no difference in OS. In the report (1994) short follow-up. C3/254 In the abstract (1997) more patients and longer follow-up
Meerwaldt 2001 (23) C	Reduced RT volume A: STNI B: MOPP/ABV × 3 + RT IF	1993–1999 St I–II 'favourable' A: 272 pts B: 271 pts	OS% A 96 B 99 ns TFFS%, at 46 m 77 99 p < 0.001	With CHT possible to reduce RT volume. RFS better with CHT, but no difference in OS. Abstract
Horning 1997 (24) C	Reduced RT volume and dose A: STNI B: VBM × 2 + RT IF + VBM × 4	1988–1995 St I–II A: 43 pts B: 35 pts	OS% A No B diff. FFP%, at 5 y 92 87	No difference in outcome. With CHT possible to reduce RT volume and dose. Alteration of the inclusion criteria during the study but probably without significance. Few patients, low power. C3/78
Rüffer 2001 (25) C	Reduced RT volume COPP/ABVD × 2 to all A: RT EF B: RT IF	1993–1998 St I–II and risk factors, St III 965 pts No. of pts in the two groups, A and B, not reported	OS% A 97 B 97 FFTF%, at 26 m 94 92 ns	Reduction of RT volume possible after CHT. Abstract, short follow up
Bonfante 2001 (26) C	Reduced RT volume and dose ABVD × 4 to all A: STNI B: RT IF	1990–1996 St IA/B, IIA, IIAE incl. bulky disease A: 66 pts B: 70 pts	OS% A 93 B 94 ns FFP%, at 10 y 97 94 ns	Reduction of RT volume possible after CHT. Abstract
Loeffler 1997 (27) C	Reduced RT dose COPP/ABVD × 2 to all A: EF 40 Gy B: EF 20 Gy, bulk 40 Gy C: EF 30 Gy, bulk 40 Gy	St I, II with risk factors, III A HD1 1984–1988 A 76 pts B 71 pts HD5 1988–1993 C111 pts	OS% A 88 B 94 C 93 ns FFTF%, at 4 y 80 79 86 ns	20 Gy is sufficient after CHT. C1/258

Abbreviations: CHT = chemotherapy; EF = extended field; IF = involved field; FFP = freedom from progression; FFTF = freedom from treatment failure; HD = high dose; m = month(s); OS = overall survival; pts = patient(s); PV = protocol violations; RT = radiotherapy; RT EF = radiotherapy extended field; RT IF = radiotherapy involved field; STNI = subtotal nodal irradiation; TF = treatment failure; y = year(s); ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; COPP = cyclophosphamide, vincristine, procarbazine, prednisone.

or more factors. The prognostic score was also predictive of overall survival. The 5-year overall survival ranged between 90 and 56% (9).

Advanced stages

See Overview 4, for a description of the trials, trial results and conclusions (32, 35, 36, 39–41).

The role of additional radiotherapy in advanced stages after chemotherapy is uncertain and controversial (see also previous reports; SBU-report 129/2, 1996 and SBU-report 155/2, 2001). It has been widely adopted without demonstration of which, if any, subsets of patients will have improved survival (28).

A further randomized trial exploring the value of additional radiotherapy after chemotherapy in advanced stages is underway in Germany (HD12) (See Addendum).

Conversion of partial to complete remission by additional radiotherapy

In a SWOG (Southwest Oncology Group) study the complete remission rate increased from 61% after chemotherapy to 80% after additional low-dose radiotherapy (IF 20 Gy) (29). In a Swedish population-based study the complete remission rate improved from 72% after 8 chemotherapy cycles to 91% after additional radiotherapy with 40 Gy to areas with residual disease (2). In an EORTC/GPMC (European Organization for the Research and Treatment of Cancer/Groupe Pierre-et-Marie-Curie) study patients in partial remission (PR) after a full course of chemotherapy received involved field radiotherapy 30/40 Gy and 72% of the patients converted to complete remission (30) and in an Italian randomized trial 14 of 15 partial responders achieved complete remission by additional radiotherapy (26).

Overview 4

Hodgkin's lymphoma. Advanced stages (in the meta-analysis intermediate stages are included)

Author Year (Ref. no.) Design	Aim/study question	Patient population	Results	Conclusion/Comments
Loeffler 1998 (32) M	a) Additional RT (ad- ditional design) A: CHT B: CHT+RT b) Substitute RT with CHT (parallel design) C: CHT ₁ +CHT ₂ or more cycles of CHT ₁ D: CHT ₁ +RT or CHT ₂ +RT	1968–1988 8 studies* St I–IV (mostly IIB–IV) CD OS A: 406 434 pts B: 512 569 pts 1972–1988 8 studies* St IIB–IV (mostly IIB– IV) DC OS C: 420 460 pts D: 417 479 pts	At 10 y a) Addition of RT improved DC with 11% p < 0.0001; TF was reduced by nearly 40% The benefit of RT was more pronounced in st I–III, in pts with mediastinal involve- ment (but not on bulky disease), in NS and LP. No benefit in st IV No difference in OS. Sign. more fatal events after RT b) No difference in DC; OS 8% better without RT P = 0.045 All pts (A, B, C, D): sign. more fatal events after RT; RR = 1.73, p = 0.005 Sign. more leukaemia related deaths after combined treatment (CHT+RT) p = 0.038	Additional RT significantly improves dis- ease control but not survival. More fatal events in the RT-arm. In parallel design trials, the same disease control in both arms, but sign. better OS without RT. The conclusions from this meta-analysis must be handled with caution as the studies were initiated 20 or more years ago with combinations of chemotherapy (mostly MOPP-based) and radiotherapy techniques that are considered outdated today. Furthermore, the extent of the irradiation and the doses was not considered and randomization was based on remission in some studies and included all patients in other studies. In the combined modality groups, more deaths from causes other than Hodgkin's lymphoma, including leukaemia were seen, but data were missing in 48% of the cases with a predominance of missing data in the combined modality group. M1/1740
Fabian 1994 (29) C Included in meta-analysis (32)	RT in CR after CHT A: MOP-BAP × 6 B: same CHT+RT IF	1978–1988* St III–IV A: 143 pts (130 no more therapy) B: 135 pts (104 received RT)	OS% RFS%, at 5 y A 79 66 B 86 ns 74 ns	No improvement in RFS (except for pts with nodular sclerosis and/or bulky disease) by adjuvant RT in CR after CHT In pts who gained planned therapy remis- sion duration was sign. better in the RT arm. C2
Coleman 1998 (39) C	Additional RT after CT? A: CVPP × 6 B: CVPP × 12 C: CVPP × 6+RT D: CVPP × 3+RT+ CVPP × 3	1975–1981 St IIIB–IV (some st IIA–B, IIIA) A: 70 pts B: 61 pts C: 59 pts D: 68 pts	No difference between the four arms concerning CR, DFS, FFS or OS	No benefit of additional RT after CHT. Alterations during the study; (maintenance therapy with chlorambucil omitted, inclu- sion of st IIIB 1979). Low power C3/258
Diehl 1995 (40) C Included in meta-analysis (32)	More CHT instead of RT in CR COPP/ ABVD × 3 to all A: RT IF B: COPP/ABVD × 1	1984–1988 St IIIB–IV 100/171 pts in CR after CHT randomized A: 51 pts B: 49 pts	% Relapse at 6 y A 25 B 20 ns No diff. in FFTF and OS	No difference between adjuvant RT or additional CHT as consolidation in com- plete remission after CHT. C2
Fermé 2000 (36) C	More CHT instead of RT in CR/PR MOPP/ABV × 6+ A: MOPP/ABV × 2 B: (S)TNI ABVPP × 6+ C: ABVPP × 2 D: (S)TNI	1989–1996 St IIIB–IV A: 92 pts B: 114 pts C: 116 pts D: 96 pts	OS%, at 5 y A 85 B 88 ns C 94 D 78 p = 0.002 DFS%, at 5 y A+C no RT 74 B+D RT 79 ns	Interim analysis. RT not superior to CHT for consolidation in CR/PR. C2/418
Brice 2001 (35) Subgroup ana- lysis of Ref. (36) above.	See Ref. (36) above	See Ref. (36), subgroup of pts with large mediastinum A+C no RT, 32 pts B+D RT, 29 pts	EFS% OS%, at 5y A+C 84 96 B+D 66 ns 97 ns	No difference between RT and CHT for consolidation therapy in patients with large mediastinum. Subgroup analysis. Few patients C3/–

Overview 4 (Continued)

Author Year (Ref. no.) Design	Aim/study question	Patient population	Results			Conclusion/Comments
Raemaekers 2001 (41) C	RT in CR after CHT A: MOPP/ABV $\times$ 6–8 B: MOPP/ABV $\times$ 6– 8+RT IF	1989–2000 St III–IV 418 pts in CR A: 161 pts B: 172 pts	RFS% A 85 B 87 ns	EFS% 82 79 ns	OS%, at 5y 89 85 ns	RT IF does not improve treatment results in stage III–IV HL-patients in CR after CHT. Abstract C3/–

Ref. no. (32): *Overall survival (OS) was evaluated in 8 studies, while disease control (DC) was evaluated in only 7 of these.

Ref. no. (29): *Initially, there was a third arm with levamisole. This was dropped in 1982 owing to slow pts accrual.

Abbreviations: CHT = chemotherapy; DC = disease control = time to failure, progression, no CR or relapse (death in CR censored); DFS = disease-free survival EF = extended field; EFS = event free survival; IF = involved field; FFP = freedom from progression; FFTF = freedom from treatment failure; HD = high dose; m = month(s); OS = overall survival; pts = patient(s); PV = protocol violations; RFS = relapse free survival; RT = radiotherapy; RT IF = radiotherapy involved field; STNI = subtotal nodal irradiation; TF = treatment failure; y = year(s); ABV(D)(PP) = doxorubicin, bleomycin, vinblastine, and (dacarbazine)(procarbazine, prednisone); COPP = cyclophosphamide, oncovine, procarbazine and prednisone; CVPP = CCNU, vinblastine, procarbazine, prednisone; MOP-BAP = nitrogen mustard, vincristine, prednisone, bleomycin, doxorubicin, procarbazine; MOPP = nitrogen mustard, vincristine, procarbazine, prednisone.

These studies may suggest a role for radiation in patients with residual disease after completion of chemotherapy, but the studies are not controlled. Furthermore, in HL it is very difficult to define PR with certainty, as there are no sensitive means to distinguish between active residual disease and fibrotic remnants. So patients classified as partial responders might be complete responders with residual abnormalities without active disease, which may continue to regress over long periods of time. In the future positron emission tomography (PET) may be a useful tool to diagnose the persistence of viable tumours in patients with residual masses (31).

Bulky mediastinum/bulky disease

See Overview 4, for a description of the trials, trial results and conclusions.

The mediastinum is involved in 70% of the cases of HL, and in one-third of these cases the involvement is considered bulky or large (mediastinal-thoracic ratio ≥ 0.33) and very large when this ratio is greater than 0.45.

Bulky mediastinum/bulky disease has generally been considered as an adverse prognostic factor with a high relapse frequency when treated with either radiotherapy or chemotherapy alone. Based on limited data, consolidating radiotherapy to patients with bulky mediastinal adenopathy is usually recommended (28) and reviewed in SBU-report 129/2, 1996. However, it is difficult to find any clear evidence for a survival benefit by this treatment.

In the international study of prognostic score in advanced HL the presence of a mediastinal mass did not appear to have a strong prognostic effect, except in the small subgroup with very large masses (9).

Longer remission duration but with no better survival was observed in a SWOG trial with 20 Gy involved field adjuvant radiotherapy for patients in complete remission after chemotherapy with bulky disease in advanced stages (29).

In a meta-analysis, disease control was no better with additional radiotherapy after chemotherapy in patients with bulky disease in intermediate and advanced stages (32–34).

In a GELA (Group d'études des lymphomes de l'adulte) trial the disease-free survival and overall survival rates for patients with bulky disease were the same for consolidation with either chemotherapy or radiotherapy (35, 36).

In an uncontrolled series the prognostic importance of bulky disease could not be proven after combined modality treatment (2, 10, 37, 38). This might indicate that radiotherapy should be used in conjunction with chemotherapy in treatment of bulky disease, but no randomized proof exists.

The literature shows that:

- There is no evidence for survival benefit of additional radiotherapy in advanced stages.
- Trials that compared additional radiotherapy with additional chemotherapy did not show any advantage of irradiation in terms of survival and in a meta-analysis the survival was significantly better without radiotherapy.
- There are reports that additional radiotherapy after a full course of chemotherapy resulting in partial remission could lead to increased complete remission rate. But there may be doubts about whether many partial remissions really represent active disease. There is no scientific proof that irradiation in these cases leads to any survival benefit.
- Radiotherapy after chemotherapy for sites with initial tumour bulk is questionable. No survival benefit or better disease control has been reported with radiotherapy. On the other hand, the prognostic importance of bulky disease was lost after combined modality treatment in uncontrolled series, which might indicate an effect of radiotherapy. Only one small randomized trial exists which showed no difference between radio-

therapy and chemotherapy as consolidation after complete remission in bulky disease.

- With the recognition that adjuvant irradiation poses an added hazard for second tumours, its use should be restricted.

Advanced stages

	1 = High	2 = Moderate	3 = Low	Total
M	1/1 740	–	–	1/1 740
C	–	3/418	4/727	7/1 145
P	1/712	2/267	–	3/979
R	1/4 695	2/362	–	3/5 057
L	1	–	–	1
O	1/44	–	–	1/44
Total	5/7 191	7/1 047	4/727	16/8 965

Abbreviations: See above.

Radiation as salvage therapy

This subject was reviewed in SBU-report 129/2, 1996. Since then, only a small number of patients treated with radiation as salvage therapy following chemotherapy failure have been reported (42–44). But this approach may be considered in selected patients with favourable factors such as limited nodal recurrence after a long disease-free interval and without previous large field radiotherapy. Comparisons with other salvage methods do not exist.

The literature shows that:

- Radiotherapy as salvage treatment might be an alternative in late limited nodal recurrence after initial chemotherapy, although no controlled trials exist but only reports on small patient materials.

Radiation as salvage therapy

	1 = High	2 = Moderate	3 = Low	Total
R	–	1/52	2/21	3/73
Total	–	1/52	2/21	3/73

Radiotherapy in conjunction with high-dose chemotherapy and stem-cell support

Patients with induction failure or early relapse (within 12 months) after chemotherapy have a poor prognosis. These patients are often treated with high-dose chemotherapy (HDCT) and stem-cell support. The value of this therapy is difficult to interpret because of patient selection and the paucity of large randomized trials with long follow-up, reviewed in SBU-report 155/2, 2001 (8).

Irradiation to involved fields is widely used in the USA either before or after high-dose therapy and sometimes

TNI; (total nodal irradiation) or TBI; (total body irradiation) either as a single dose or in a fractionated manner. Sometimes accelerated fractionation is used (45). Radiotherapy to involved fields (often meaning mantle or inverted Y) with or without TNI/TBI incorporated into the induction chemotherapy prior to or following HDCT is reported in small, uncontrolled, retrospective series with heterogeneous applications of radiotherapy (45–50). Some data point to better local disease control with involved field radiotherapy but there is no evidence that this translates into longer survival.

Furthermore, it is difficult to distinguish between the contribution of the radiotherapy and the effect of chemotherapy towards the outcome in these series.

In a report from Toronto, treatment-related mortality (TRM) was noticed in one-third of the patients with thoracic radiotherapy prior to HDCT in contrast to no TRM in patients with radiotherapy to extra-thoracic areas. The mortality was mainly due to pulmonary toxicity. The authors recommended the use of radiotherapy after HDCT to decrease TRM (51). At Stanford University they now prefer to give radiotherapy after HDCT and to smaller volumes because of unacceptable toxicity from irradiation before HDCT (52).

The value of radiotherapy in conjunction with HDCT has not been established by randomized trials but one prospective randomized trial from Rochester in the USA is under way (53).

The literature shows that:

- Radiotherapy in conjunction with high-dose chemotherapy and stem-cell support may increase local disease control but there is no evidence of improved survival.
- Radiotherapy, especially thoracic, prior to high-dose chemotherapy may contribute to high rates of TRM.

Radiotherapy in conjunction with high-dose chemotherapy and stem-cell support

	1 = High	2 = Moderate	3 = Low	Total
R	–	4/224	4/196	8/420
O	1	–	–	1
Total	1	4/224	4/196	9/420

Radiation technique and quality assurance studies

Some of the late effects we observe today are the result of treatment techniques that are no longer in use. Dose variations in the past may have led to excessive normal tissue injury as well as inadequate disease control. Many modifications in the current practice depend on the observed complications of past treatment.

Well-designed, quality-assurance programmes ought to clarify in what way different practices affect both the

normal tissues and the disease control (54). Quality control in radiotherapy for Hodgkin's disease became a major focus of attention in the 1990s.

Many discrepancies that might influence the outcome were found in a patterns of care study from the USA surveying data concerning planning from 61 radiotherapy institutions to assess compliance to guidelines in the late 1980s. Surprisingly, only 80% of the centres used treatment with daily AP/PA fields, hardly any in vivo dosimetry was used. Furthermore, 70% did not use dose compensation, more than half of the institutions did not use immobilization of the patients and 30% did not calculate a gap between the upper and lower fields (55).

An experimental dosimetry study from 23 centres in Australia and New Zealand has shown a wide variation in the dose delivered within a mantle field and within the centres surveyed (56). In a study to measure the mantle planning in Australia and New Zealand a chest x-ray was sent to radiation oncologists asking them to mark the lung blocks on the x-ray. In 44 replies the mediastinal coverage was judged to be inadequate in at least 50% of the cases (57). The GHSG (German Hodgkin Study Group) conducted a randomized multicentre study between 1988 and 1993 with different radiation doses in patients with early-stage HL treated with radiotherapy only (15). A panel of four experienced chairpersons from different departments of radiation therapy prospectively reviewed the planning and verification films, the radiotherapy reports charts, the technique and the dosimetry. If at least three out of four panelists voted for protocol violations (PV), about one-third of the patient's radiotherapy was assigned as PV, i.e. mainly inadequate treatment volume or dose, protracted treatment time or technical inadequacies. Nineteen percent of the patients with PV relapsed compared with 11% without PV. Freedom from treatment failure at 5 years was 82% in patients treated without PV compared with 70% in patients with PV ($p < 0.04$).

In a randomized SWOG trial, studying the value of adjuvant radiotherapy in patients in complete remission after chemotherapy, a quality assurance review of the radiotherapy was performed. In 17% of the patients there was considered to be major protocol violations. Forty-four percent of these patients relapsed compared with only 10% of the patients who had received radiotherapy according to protocol. But other patient characteristics of the two groups were not given (29). The quality control programme of the radiation therapy in the EORTC H8 multicentre study in early stages revealed a 14% major deviation related to the treated volumes and 40% related to the dose (58).

The literature shows that:

- Even recent reports show that the problems of technical accuracy are still a major factor in the irradiation of large volumes in HL.

- Awareness of the wide variations in radiotherapy practice is essential in evaluating the value of irradiation and the overall treatment outcome.
- Furthermore, the mostly very sparse information about the radiation technique and how the doses are specified in articles concerning radiotherapy in lymphomas makes it problematic to interpret and compare the results of radiotherapy from different centres and studies.

Radiation technique and quality assurance studies

	1 = High	2 = Moderate	3 = Low	Total
C	–	2/623	–	2/623
R	2/436	–	–	2/436
O	2	–	–	2
Total	4/436	2/623	–	6/1 059

Long-term sequelae

Fifteen years after diagnosis, mortality from causes other than HL begin to exceed deaths from HL. These causes of death are mostly treatment related and increase steadily after 15 years. However, the absolute excess risk of death during each five-year follow-up interval is less for patients treated in more recent years (1980–1995) than in the prior treatment era (1962–1980) in a report from the Stanford University (59). From The Netherlands a 20-year cumulative risk of dying from HL of 33% and from all other causes 20% is reported (60).

Secondary malignancies

The 20-year cumulative risk of developing a secondary malignancy after treatment for HL is 15–20%, which means an almost fourfold excess as compared with the risk expected in the general population. The relative risk of a second malignancy after treatment for HL ranges between 2.2 and 6.4 in reports from Canada, Stanford, the United Kingdom and The Netherlands (60–63).

Myelodysplastic syndrome (MDS)/acute non-lymphatic leukaemia (ANLL). ANLL has been related mainly to alkylating agents, especially MOPP therapy. A decreasing risk of ANLL is reported for patients treated in the 1980s when the use of MOPP diminished compared with patients treated in the 1970s (60). Radiotherapy alone does not increase the risk of leukaemia (60, 63). There are different opinions as to whether combined modality treatment with addition of radiotherapy to chemotherapy confers a higher risk over chemotherapy alone (28). Recently, topoisomerase II inhibitors, especially etoposide, with a known leukaemogenic effect have been introduced in the therapy arsenal, often together with radiotherapy. What this means for the future, we do not know yet.

After high-dose chemotherapy with autografting for HL and NHL an actuarial incidence of 4–18% for MDS/ANLL

is observed with 5–15 years' follow-up (64). Radiotherapy is often incorporated in the induction treatment of these patients, especially in the USA. It is unclear whether MDS/ANLL is related to the initial therapy, treatments in conjunction with HDCT, or a result of cumulative effects of all these exposures (64). Retrospective data to evaluate risk factors for therapy-related MDS/ANLL in these patients have been collected. Multivariate analysis revealed an association between pretransplant radiation and the risk of MDS/ANLL, but failed to show any association with pretransplant chemotherapy or conditioning regimens with exception of patients who had received etoposide for stem-cell mobilization. These patients had a 12-fold increased risk of developing ANLL (65).

Secondary non Hodgkin-lymphoma (NHL). The relationship of secondary NHL after therapy for HL is poorly understood. The risk for developing secondary NHL is independent of the initial therapy, with similar risks for primary radiotherapy, combined modality treatment and chemotherapy alone in some series (62, 63), but in another report combined modality treatment led to a higher risk (60). It has been speculated that in some cases NHL may represent a natural evolution and in other cases that the immunological deficiency or perturbation related to HL and/or the treatment may cause the development of NHL (28).

Secondary solid tumours. Secondary solid tumours have a much longer latent period than secondary leukaemias and NHL. Radiotherapy is considered to have the major carcinogenic role in the development of solid cancers after treatment for HL (28). The highest risk for developing secondary solid tumours has been observed among patients who had received primary combined treatment modality followed by more treatment courses for recurrences (60). The long-term risks of secondary tumours are dependent on age at treatment. It has been observed that the relative risk of secondary solid tumours of many types is greatly increased with younger age at first treatment but also there is a decline in the relative risk, as the young patients grow older (> 20 years' follow-up) (66). For adult and older patients, no plateau or decline in the relative risk of secondary solid tumours after long follow-up has been observed (63, 67).

Lung cancer

Lung cancer is the most common type of secondary cancer after treatment for HL. A twofold to eightfold excess risk of lung cancer compared with the risk in the general population is observed five or more years after HL treatment and no peak is reached (63). There is general agreement of an excess risk after irradiation but not on the contribution of chemotherapy (63, 66). Smoking history, particularly continuance of smoking after treatment of HL markedly increases the risk (28).

Breast cancer

Breast cancer is the most common secondary malignancy in women after therapy for HL. The risk is high for patients irradiated between puberty and 30 years of age but there is little or no increased risk for women irradiated after 30 years of age. The median time to presentation of secondary breast cancer is about 15 years (range 4–20) after treatment (68). Although the incidence increases with time after therapy the relative risk diminishes after 20 years (66). The increased risk is confined to patients treated with radiotherapy alone (63). No case of male breast cancer has been reported after irradiation for HL. These tumours appear within or at the edge of the treatment fields (69).

Other secondary solid tumours

The relative risk of developing other solid tumours is also increased. A significantly increased risk of cancers in stomach, colon, tongue, mouth, pharynx, liver and soft tissue was only found in patients who had received combined modality therapy. Cancer of the small intestine, bone and melanoma occurred solely in patients treated with radiotherapy (with or without chemotherapy) and thyroid cancer risk was significantly increased only in radiotherapy-treated groups (63).

Cardiac complications

Cardiovascular complications after radiotherapy of mediastinum, mainly mantle therapy, constitute the second most frequent cause of treatment-related mortality in HL patients. Cardiac deaths have been responsible for about one-quarter of the mortality from causes other than HL and constitute nearly 5% of the deaths in the entire HL population (59, 80). There is an increased relative risk of cardiac death during the initial 5 years after treatment with a slowly continuing increase in patients followed for more than 20 years. Young age at the time of irradiation increased the risk for both myocardial infarction and other cardiac deaths. With modern techniques, including additional cardiac shielding, the cardiac morbidity has decreased but the incidence of myocardial infarction has not changed (62). In one study no increased risk for cardiac death was found when doses of 30 Gy or less were used (62), but this has not been reported in any other study.

Myocardial infarction. Myocardial infarctions constitute more than two-thirds of the cardiac mortality observed in irradiated HL patients at Stanford (59). In a study from Switzerland, a high relative risk for myocardial infarction and sudden death was found in males with risk factors for cardiovascular disease but not for females or males without risk factors (71). Another study showing increased risk for fatal myocardial infarction also found that all the deceased patients had at least one risk factor for cardiovascular disease (72). Despite low mean fraction dose and moderate total dose, a high incidence of ischaemic cardiac deaths was

observed in a report from The Netherlands (70), but in a report from Canada no increased risk of death from myocardial infarction was found (61).

Other cardiac deaths. Radiation damage to the pericardium, the myocardium and heart valves frequently follows mantle irradiation. These complications were often seen after radiotherapy in the 1960s and early 1970s. However, the risk of cardiac deaths from causes other than myocardial infarction has markedly diminished with modern radiation technique (62).

The literature shows that:

- With long-term follow-up mortality from causes other than HL begins to exceed deaths from HL. This excess risk of death is attributed mainly to secondary malignancy and cardiac deaths, especially myocardial infarction.
- The 20-year cumulative risk of developing a secondary malignancy after treatment for HL is 15–20%, almost a fourfold excess as compared with the risk expected in the general population.
- The risk of leukaemia is not increased by radiotherapy alone. There are different opinions on whether or not combined modality treatment with radiotherapy and chemotherapy confers a higher risk than chemotherapy alone.
- Development of NHL after treatment of HL may be multifactorial but is poorly understood. The role of radiotherapy is unclear.
- Secondary solid tumours have a long latent period, median time over 10 years. Radiotherapy is considered to have a major carcinogenic role in the development of solid cancers after treatment for HL. The relative risk of secondary solid tumours of many types is greatly increased with younger age at treatment.
- Cardiovascular disease is the second most frequent cause of treatment-related mortality in HL patients and myocardial infarctions constitute more than two-thirds. Mediastinal irradiation, mainly mantle therapy, is clearly associated with these late effects.
- Changes in treatment introduced during the past few decades seem to have reduced the risk of death from secondary cancers and cardiovascular disease, although several more years of follow-up will be required to confirm these data.
- An important issue is the dose effect in radiotherapy. Is there any safe dose, especially in combined modality therapy programmes, so that the risk for secondary tumours or cardiac disease will not be increased?
- It might be that not only the given therapy is responsible for the secondary malignancies but also that the immune defect in HL patients predispose the development of other malignancies. There are no comparative studies with other cured cancer patient groups concerning the frequency of secondary malignancies.

Long-term sequelae

	1 = High	2 = Moderate	3 = Low	Total
R	9/11 857	1/258	–	10/12 115
L	3	–	–	3
O	1	–	–	1
Total	13/11 857	1/258	–	14/12 115

LITERATURE

The articles on which the conclusions in this report were based were classified and graded as follows (number of studies/number of patients)

	1 = High	2 = Moderate	3 = Low	Total
M	2/5 628	–	–	2/5 628
C	1/258	5/1 089	6/663	12/2 010
P	1/712	2/267	–	3/979
R	12/16 988	11/1 414	6/217	29/18 619
L	4	–	–	4
O	7/44	1	–	8/44
Total	27/23 630	19/2 770	12/880	58/27 280

Abbreviations: See above.

CONCLUSIONS AND COMMENTS

Solid scientific documentation shows that in younger patients with Hodgkin's lymphoma more than 80% in the early stages of disease and 60–70% in advanced stages are now cured owing to the development of radiotherapy and combination chemotherapy. ((9) R1, (32) M1, (11) L1, (13) M1).

Long-term follow up reveals that after 15 to 20 years the mortality from HL in early and intermediate stages is exceeded by other causes of death, mostly secondary malignancies and cardiac deaths, especially myocardial infarction. ((61) R1, (62) R1, (59) R1, (11) L1, (63) R1, (60) R1, (66) R1).

Convincing data show that radiotherapy plays a major role in the development of solid cancers and cardiovascular disease, but no randomized trials have been performed. ((28) L1, (68) L1, (62) R1, (59) R1, (70) R2, (63) R1, (60) R1, (66) R1).

During the past decade increasing awareness of fatal long-term sequelae has fundamentally changed treatment strategies in early and intermediate stages. A thorough long-term follow-up is essential to evaluate the effects of the modifications of the therapy.

In early stages extended field irradiation is now replaced by brief chemotherapy followed by limited radiotherapy to decrease late sequelae. This approach is strongly supported

by early reports from randomized trials. Final results cannot be fully evaluated for many years. ((23)C3, (21)C3, (22)C3, (19)C3).

The optimal radiation dose and volume after chemotherapy have not been defined or if irradiation is needed at all. Several studies are now under way.

Two recently reported randomized trials on intermediate stages indicate that combined modality therapy is preferable and that the involved field could replace extended field irradiation. It is still too early to draw any firm conclusions (26) C3, (25) C3).

In advanced stages there is no evidence to suggest any survival benefit from additional radiotherapy. ((39) C3, (40) C2, (29) C2, (36) C2, (32) M1, (41) C3).

The role of radiotherapy in the case of residual tumour and bulky disease still remains controversial. (*Pro* (29) C2, *Con* (26) C3, (36) C2, (32) M1, *Ambiguous* (2) R2, (10) P1, (37) P2, (38) R2).

There is no scientific support for improved survival with radiotherapy in conjunction with high-dose chemotherapy with stem-cell support. ((45) R2, (46) R3, (47) R3, (48) R3, (49) R2, (50) R3).

Radiotherapy as salvage treatment might be an alternative in late limited nodal recurrence after initial chemotherapy. However, the body of knowledge is small. ((42) R3, (43) R3, (44) R2).

The role of radiotherapy in the treatment of HI is decreasing.

REFERENCES

1. Cancer incidence in Sweden 1999. Stockholm: National Board of Health and Welfare, Centre for Epidemiology. The Cancer Registry, 2001.
2. Amini R-M, Enblad G, Gustavsson A, et al. Treatment outcome in patients younger than 60 years with advanced stages (IIB–IV) of Hodgkin's disease: The Swedish national health care programme experience. *Eur J Haematol* 2000; 65: 379–89 (R2/307).
3. Glimelius B, Kälkner M, Enblad G, et al. Treatment of early and intermediate stages of supradiaphragmal Hodgkin's disease: the Swedish national care programme experience. *Ann Oncol* 1994; 5: 809–16 (R2/210).
4. Molin D, Enblad G, Gustavsson A, et al. Early and intermediate stage Hodgkin's lymphoma-report from the Swedish National Care Programme. *Eur J Haematol* 2003; 70: 172–80 (R2/308).
5. Enblad G, Gustavsson A, Sundström C, Glimelius B. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. *Acta Oncol* 2002; 41: 659–67 (R2/139).
6. Carli PM, Coebergh JWW, Verdecchia A and the EURO-CARE working group. Variation in survival of adult patients with haematological malignancies in Europe since 1978. *Eur J Cancer* 1998; 34: 2253–63 (O1).
7. Kennedy BJ, Fremgen AM, Menck HR. The National Cancer Data Base report on Hodgkin's disease for 1985–1989 and 1990–1994. *Cancer* 1998; 83: 1041–7 (O1).
8. Brandt L, Kimby E, Nygren P, et al. A systematic overview of chemotherapy effects in Hodgkin's disease. *Acta Oncol* 2001; 40: 185–97 (O1).
9. Hasenclever D, Diehl V for the International prognostic factors project on advanced Hodgkin's disease. A prognostic score for advanced Hodgkin's disease. *N Engl J Med* 1998; 339: 1506–14 (R1/4695).
10. Franklin J, Paulus U, Lieberz D, Breuer H, Tesch H, Diehl V for the German Hodgkin Lymphoma Study Group. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? *Ann Oncol* 2000; 11: 617–23 (P1/712).
11. Ng AK, Hoppe RT, Mauch PM. Life expectancy of patients with Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, et al., (eds). *Hodgkin's disease*. Philadelphia: Lippincott Williams and Wilkins; 1999. p. 585–605 (L1).
12. Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease. *Clin Lab Haem* 1998; 20: 95–9. (Excluded randomized study).
13. Specht L, Gray RG, Clarke MJ, Peto R for the International Hodgkin's Disease Collaborative Group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3 888 patients. *J Clin Oncol* 1998; 16: 830–43 (M1/3888).
14. Brincker H, Bentzen SM. A re-analysis of available dose-response and time-dose data in Hodgkin's disease. *Radiation Oncol* 1994; 30: 227–30 (O2).
15. Dühmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. *Int J Radiat Oncol Biol Phys* 1996; 36: 305–10 (C2/345).
16. Mendenhall NP, Rodrigue LL, Moore-Higgs GJ, et al. The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control. *Int J Radiat Oncol Biol Phys* 1999; 44: 551–61 (R2/169).
17. Sieber M, Rueffer U, Tesch H, et al for the GHSG. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: interim analysis of the HD7 trial of the German Hodgkin's lymphoma study group (GHSG). *Leuk Lymphoma* 2001; 42 (Suppl 2): 52. Abstract.
18. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. *J Clin Oncol* 2001; 19: 4238–44 (C2/326).
19. Radford JA. UK studies in early stage/low risk Hodgkin's lymphoma. *Leuk Lymphoma* 2001; 42 (Suppl 2): 12–3. Abstract.
20. Enrici RM, Anselmo AP, Donato V, et al. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD. *Haematologica* 1999; 84: 917–23 (C3/73).
21. Noordijk EM, Carde P, Mandard A-M, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. *Ann Oncol* 1994; 5 (Suppl 2): 107–12 (C3/254).
22. Noordijk EM, Carde P, Hagenbeek A, et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF', 'H7-F' and

- 'H7-U'. *Int J Radiat Oncol Biol Phys* 1997; 39 (Suppl 173): Abstract.
23. Meerwaldt JH, Eghbali H, Fermé C, et al. for the EORTC lymphoma group and the Groupe d'études des lymphomes de l'adulte (GELA). Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favourable supradiaphragmatic clinical stages I–II Hodgkin's lymphoma: preliminary results of the EORTC-GELA H8-F randomized trial (# 20931) in 543 patients. *Leuk Lymphoma* 2001; 42 (Suppl 2): 12. Abstract.
 24. Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. *J Clin Oncol* 1997; 15: 1736–44 (C3/78).
 25. Rüffer J-U, Sieber M, Pfistner B, et al. for the German Hodgkin's study group (GHSG). Extended versus involved field radiation following chemotherapy for intermediate stage Hodgkin's disease: interim analysis of the HD8 trial. *Leuk Lymphoma* 2001; 42 (Suppl 2): 54. Abstract.
 26. Bonfante V, Viviani S, Devizzi L, et al. Ten-years' experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved field (IFRT) in early stage Hodgkin's disease (Hd). 367th Ann Meeting Am Soc Clin Oncol 2001; Abstract 1120.
 27. Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship at complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. *J Clin Oncol* 1997; 15: 2275–87 (C1/258).
 28. Aisenberg AC. Problems in Hodgkin's disease management. *Blood* 1999; 93: 761–79 (L1).
 29. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. *Ann Intern Med* 1994; 120: 903–12 (C2/278).
 30. Raemaekers J, Burgers M, Henry-Amar M, et al. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. *Ann Oncol* 1997; 8 (Suppl 1): 111–4 (P2/122).
 31. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. *Ann Oncol* 1999; 10: 1181–4 (O1/44).
 32. Loeffler M, Brosteanu O, Hasencleaver D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. *J Clin Oncol* 1998; 16: 818–29 (M1/1740).
 33. Andrieu JM, Yilmaz U, Colonna P. MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians. *J Clin Oncol* 1999; 17: 730–2.
 34. Loeffler M, Brosteanu O, Hasencleaver D. In reply. *J Clin Oncol* 1999; 17: 732–4.
 35. Brice P, Colin P, Berger F, et al. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy. *Cancer* 2001; 92: 453–9 (C3/–).
 36. Fermé C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'études des lymphomes de l'adulte H89 trial. *Blood* 2000; 95: 2246–52 (C2/418).
 37. Gobbi PG, Pieresca C, Ghirardelli ML, et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. *Blood* 1998; 8: 2704–12 (P2/145).
 38. Mendenhall NP, Bennett CJ, Lynch JW. Is combined modality therapy necessary for advanced Hodgkin's disease? *Int J Radiat Oncol Biol Phys* 1997; 38: 583–92 (R2/55).
 39. Coleman M, Rafta S, Probert KJ, et al. Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival—results of a cancer and leukemia group B study. *Int J Radiat Oncol Biol Phys* 1998; 41: 639–45 ((C3/258).
 40. Diehl V, Loeffler M, Pfreundschuh M, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. *Ann Oncol* 1995; 6: 901–10 (C2/100).
 41. Raemaekers JMM, Aleman BM P, Henry-Amar M, et al. for the EORTC lymphoma group. Involved field irradiation (IFRT) versus no further treatment in patients with stage III/IV Hodgkin's lymphoma in complete remission after MOPP/ABV: first results of the randomized EORTC trial # 20884. *Leuk Lymphoma* 2001; 42 (Suppl 2): 14–5. Abstract.
 42. O'Brien PC, Parnis FX. Salvage radiotherapy following chemotherapy failure in Hodgkin's disease—What is its role? *Acta Oncol* 1995; 34: 99–104 (R3/11).
 43. Pezner RD, Lipsett JA, Vora N, Forman SJ. Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval. *Int J Radiat Oncol Biol Phys* 1994; 30: 965–70 (R3/10).
 44. Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. *Int J Radiat Oncol Biol Phys* 1997; 39: 599–607 (R2/52).
 45. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. *Blood* 2001; 97: 616–23 (R2/65).
 46. Mundt AJ, Sibley G, Williams S, et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1995; 33: 261–70 (R3/54).
 47. Nademanee A, O'Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. *Blood* 1995; 85: 1381–90 (R3/85).
 48. Pezner RD, Nademanee A, Niland JC, et al. Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. *Radiation Oncol* 1995; 34: 23–9 (R3/29).
 49. Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. *Int J Radiat Oncol Biol Phys* 1996; 36: 3–12 (R2/100).
 50. Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide±cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. *Blood* 1994; 83: 1193–9 (R3/28).
 51. Tsang RW, Gospodarowicz MK, Suthcliffe SB, et al. Thoracic radiation therapy before autologous bone marrow transplanta-

- tion in relapsed or refractory Hodgkin's disease. *Eur J Cancer* 1999; 35: 73–8 (R2/59).
52. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. *Blood* 1997; 89: 801–13 (R2/–).
 53. Constine LS, Rapaport A P. Hodgkin's disease, bone marrow transplantation, and involved field radiation therapy: coming full circle from 1902 to 1996. *Int J Radiat Oncol Biol Phys* 1996; 36: 253–5 (O1).
 54. Zackrisson B, Mattsson S, Kjellén E, et al. and the Swedish Cancer Society Investigation Group. Research and development of radiation therapy in clinical routines. *Acta Oncol* 2003; 42: 115–22.
 55. Hughes DB, Smith AR, Hoppe R, et al. Treatment planning for Hodgkin's disease: a patterns of care study. *Int J Radiat Oncol Biol Phys* 1995; 33: 519–24 (R1/275).
 56. Amies C, Rose A, Metcalf P, Barton M. Multicentre dosimetry study of mantle treatment in Australia and New Zealand. *Radiother Oncol* 1996; 40: 171–80 (O1).
 57. Barton MB, Rose A, Lonergan D, et al, on behalf of the Australasian radiation oncology lymphoma group. Mantle planning: report of the Australasian radiation oncology lymphoma group film survey and consensus guidelines. *Australas Radiol* 2000; 44: 433–8 (O1).
 58. Hennequin C, Carrie C, Hofstetter S, Cosset JM. Le controle de qualite de la radiotherapie dans la Maladie de Hodgkin. *Cancer Radiother* 1999; 3: 187–90 (R1/161).
 59. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. *Ann Oncol* 1997; 8 (suppl 1): 115–8 (R1/2498).
 60. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. *J Clin Oncol* 1994; 12: 312–25 (R1/1939).
 61. Brierley JD, Rathmell AJ, Gospodarowicz MK, et al. Late effects of treatment for early-stage Hodgkin's disease. *Br J Cancer* 1998; 77: 1300–10 (R1/611).
 62. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. *Semin Radiat Oncol* 1996; 6: 2252 (R1/–).
 63. Swerdlow AJ, Barber JA, Vaughan Hudson G, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. *J Clin Oncol* 2000; 18: 498–509 (R1/5519).
 64. Bhatia S. Late effects of hematopoietic cell transplantation. *Educational Book. Am Soc Clin Oncol* 2001; 373–85 (L1).
 65. Krishnan A, Bhatia S, Slovak M L, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. *Blood* 2000; 95: 1588–93 (R1/612).
 66. van Leeuwen FE, Klokman WJ, van't Veer M B, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. *J Clin Oncol* 2000; 18: 487–97 (R1/–).
 67. Travis L. Therapy-associated secondary solid cancer. *Acta Oncol* 2002; 41: 323–33 (O1).
 68. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. *Cancer Treat Rev* 2000; 26: 291–302 (L1).
 69. Christie DRH, Wills R, Drew J F, Barton M B. The doses received by the breast during mantle radiotherapy. *Int J Radiat Oncol Biol Phys* 1998; 41: 223–6 (O1).
 70. Reinders JG, Heijmen BJM, Olofsen-van Acht MJJ, et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. *Radiother Oncol* 1999; 51: 35–42 (R2/258).
 71. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. *Radiother Oncol* 1998; 46: 51–62 (R1/352).
 72. King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1996; 36: 881–9 (R1/326).

ADDENDUM*Early and intermediate stages (ongoing trials)*

Radiotherapy alone versus chemotherapy

NCI-Canada/ECOG	STNI/inverted Y vs. ABVD $\times$ 4–6	Open
Favourable		

Radiotherapy alone versus chemotherapy plus radiotherapy

UK lymphoma group	Mantle vs. VAPEC-B $\times$ 1 + IF (30–40 Gy)	Open
-------------------	---	------

Chemotherapy plus radiotherapy versus chemotherapy alone

MSKCC	ABVD $\times$ 6 + mantle /inverted Y (STNI/TNI for st IIIA) vs. $\times$ ABVD $\times$ 6	Recently closed no results
NCI-Canada/ECOG	ABVD $\times$ 2 + STNI/inverted Y vs. ABVD $\times$ 4–6	Unfavourable
GHSG HD 13	ABVD $\times$ 2 + IF 20–30 Gy vs. ABVD $\times$ 4–6	Open
CALGB	ABVD $\times$ 4 + IF vs. ABVD $\times$ 6	Soon to be started

Evaluating radiation dose after chemotherapy

GHSG HD 10	ABVD $\times$ 2 + IF 30 Gy or 20 Gy vs. ABVD $\times$ 4 + IF 30 Gy or 20 Gy	Open
GHSG HD 11	ABVD $\times$ 4 + IF 30 Gy or 20 Gy vs. BEACOPP base $\times$ 4 + IF 30 Gy or 20 Gy	Open
EORTC H9-F	EBVP $\times$ 6 + IF 36 Gy vs. EBVP $\times$ 6 + IF 20 Gy vs. 6 $\times$ EBVP alone	Open

Advanced stages: stage III and IV (st IIB with risk factors)

The role of additional radiotherapy

GHSG HD 12	BEACOPP escalated $\times$ 8 + 30 Gy bulk or 0 RT vs. BEACOPP escalated $\times$ 4 + BEACOPP base $\times$ 4 + 30 Gy bulk or 0 RT	Open
------------	---	------

Abbreviations:

ANLL; Acute non-lymphocytic leukaemia
 AP/PA; anterior-posterior/posterior-anterior (radiation fields)
 CALGB; Cancer and Leukaemia Group B
 EF; extended field
 EORTC; European Organization for the Research and Treatment of Cancer
 GELA; Groupe d'études des Lymphomes de l'adulte
 GHSG; German Hodgkin Study Group
 GPMC; Groupe Pierre-et-Marie-Curie
 HDCT; high-dose chemotherapy
 HL; Hodgkin's lymphoma;
 IF; involved field

IPS; International Prognostic Score
 MDS; myelodysplastic syndrome
 MSKCC; Memorial Sloan Kettering Cancer Centre
 NHL; non-Hodgkin lymphoma
 PET; positron emission tomography
 PV; protocol violations
 STNI; subtotal nodal irradiation
 SWOG; Southwest Oncology Group
 TBI; total body irradiation
 TNI; total nodal irradiation
 TRM; treatment related mortality